CinCor Pharma, Inc. CINC 深 沪
等待开盘 08-26 09:30:00 美东时间
29.06
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 29.06
- 总市值 127.24万
- 52周最高 43.15
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 10.53
- 委 比 0.00%
- 总股本 4.38万
- 历史最高 43.15
- 量 比 0
- 振 幅 0.00%
- 历史最低 10.53
- 每 手 1
- 风险率 0.07%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多产业新闻 | 治疗高血压，阿斯利康“first-in-class”小分子获FDA批准
阿斯利康（AstraZeneca）公司今日宣布，“first-in-class”醛固酮合酶抑制剂Baxfendy（baxdrostat）已获得美国FDA批准，与...
05-19 07:32
Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer
Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates
04-02 20:11
Eli Lilly Could Rejoin Abivax Bidding If AstraZeneca Misses Deadline
AstraZeneca holds exclusive access to Abivax's data room until March 23 as Eli Lilly waits. Key Phase 3 trial results expected in June.
03-12 18:46
AstraZeneca succeeds in late-stage trial for blood pressure therapy
AstraZeneca (NASDAQ:AZN) announced on Tuesday that a blood pressure therapy it acquired through its 2023 acquisition of CinCor Pharma has reached its primary goal in a Phase 3 trial, offering new hope...
2025-10-07 19:47
AstraZeneca is said to seek approval for antihypertensive this year
AstraZeneca (NASDAQ:AZN) plans to submit regulatory filings for its blood pressure treatment baxdrostat by the end of this year, seeking approval for the small molecule therapy potentially in 2026, Re...
2025-08-31 00:03
